Webcast Provides Perspective on Generic Imatinib

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time in the United States through Sun Pharmaceuticals. In response to this transition, the LRG provided an educational Webinar to the CML and GIST communities on March 18th entitled “Generic Imatinib: Gaining Perspective.”